Hanmi Pharm. Co., Ltd. (KRX: 128940)

Market Cap	3.19T
Revenue (ttm)	1.57T
Net Income (ttm)	160.66B
Shares Out	12.68M
EPS (ttm)	12,667.32
PE Ratio	19.85
Forward PE	20.62
Dividend	500.00 (0.21%)
Ex-Dividend Date	Jun 27, 2024

Volume	34,525
Average Volume	47,798
Open	236,500
Previous Close	234,000
Day's Range	235,500 - 242,000
52-Week Range	233,000 - 375,000
Beta	0.52
RSI	29.67
Earnings Date	Feb 4, 2025

About Hanmi Pharm.

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 2,330
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 128940

Financial Performance

In 2023, Hanmi Pharm.'s revenue was 1.49 trillion, an increase of 11.97% compared to the previous year's 1.33 trillion. Earnings were 146.23 billion, an increase of 76.63%.